Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis.
about
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 updateLETTER TO THE EDITOR Subcutaneous (SC) Methotrexate (MTX) is Better and Well-Tolerable than Oral MTX in Rheumatoid Arthritis Patients, Switched from Oral to SC Administration Due to Gastrointestinal Side EffectsOutcomes related to methotrexate dose and route of administration in patients with rheumatoid arthritis: a systematic literature reviewFactors Associated with Myelosuppression Related to Low-Dose Methotrexate Therapy for Inflammatory Rheumatic Diseases.EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugsManagement of rheumatoid arthritis: consensus recommendations from the Hong Kong Society of RheumatologyMethotrexate in rheumatoid arthritis is frequently effective, even if re-employed after a previous failure.Specific management of post-chikungunya rheumatic disorders: a retrospective study of 159 cases in Reunion Island from 2006-2012.Comparing the long-term clinical outcome of treatment with methotrexate or sulfasalazine prescribed as the first disease-modifying antirheumatic drug in patients with inflammatory polyarthritisComparison of two different folic acid doses with methotrexate--a randomized controlled trial (FOLVARI Study).Step-up combination versus switching of non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a retrospective observational study.Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score.The rapid kinetics of optimal treatment with subcutaneous methotrexate in early inflammatory arthritis: an observational studyAre American College of Rheumatology 50% response criteria superior to 20% criteria in distinguishing active aggressive treatment in rheumatoid arthritis clinical trials reported since 1997? A meta-analysis of discriminant capacities.Ascendancy of weekly low-dose methotrexate in usual care of rheumatoid arthritis from 1980 to 2004 at two sites in Finland and the United States.Mycobacterium intracellulare Pulmonary Disease with Endobronchial Caseation in a Patient Treated with Methotrexate.Depicting and comparing the time to normalize "erythrocyte sedimentation rate" following two combination therapies in rheumatoid arthritis patients: a randomized clinical trialTreatment of rheumatoid arthritis: a global perspective on the use of antirheumatic drugsDevelopments in the clinical understanding of rheumatoid arthritis.Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regenerationPerioperative management of medications used in the treatment of rheumatoid arthritis.Certolizumab Pegol Efficacy Across Methotrexate Regimens: A Pre-Specified Analysis of Two Phase III Trials.Long-term use of adalimumab in the treatment of rheumatic diseases.NF-κB signaling and bone resorption.Low serum levels of myeloid progenitor inhibitory factor-1 predict good response to methotrexate in rheumatoid arthritisDrug interaction between methotrexate and salazosulfapyridine in Japanese patients with rheumatoid arthritis.Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task forceMethotrexate induces production of IL-1 and IL-6 in the monocytic cell line U937.One-Carbon Metabolism in Health and Disease.Twenty-Year Outcome and Association Between Early Treatment and Mortality and Disability in an Inception Cohort of Patients With Rheumatoid Arthritis: Results From the Norfolk Arthritis Register.Oral janus kinase inhibitor for the treatment of rheumatoid arthritis: tofacitinib.Have the 10-year outcomes of patients with early inflammatory arthritis improved in the new millennium compared with the decade before? Results from the Norfolk Arthritis Register.Subcutaneous methotrexate for symptomatic control of severe recalcitrant psoriasis: safety, efficacy, and patient acceptability.The science of rheumatoid arthritis: a prelude.Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in tNon-alcoholic steatohepatitis-like pattern in liver biopsy of rheumatoid arthritis patients with persistent transaminitis during low-dose methotrexate treatment
P2860
Q26859134-2B660C9C-7A23-440A-A6B3-2BB4993DA288Q26861182-DAC3ACC0-3E18-4F44-AFF3-4CFCCE1D06E9Q26995202-F0AE45DF-D14F-4F2D-8802-9B77D688082FQ33431836-D9916B13-864D-48D2-A3AD-60F3250478A2Q34110066-626D47CC-E9F4-42F5-9692-F9387C92114DQ34641300-6CACB39A-C80E-4AAE-8E51-3F6B0E467EA5Q34896997-34FDE871-C3C5-4DA7-A85B-E2394B177564Q35168183-5467C7A0-ADE7-42E5-9DC0-F267D03639B9Q35638194-F7AF041C-5C75-45EB-94C1-FD8590ABACB8Q35789299-3792FBE2-9AD5-411B-B855-0CC054A10457Q35953458-BEEE0347-F368-48DA-BEDB-B74D5B6DD745Q36013828-3FD38332-331B-4AA4-AD72-5F956F16253BQ36112213-2BA46382-52ED-4F8B-A9B9-43C3054E445BQ36408155-E2855939-12E8-4229-A096-69644A521BCFQ36893038-B25ACD9F-9ABE-4C84-BDE5-2379DD7008E1Q37090053-18DC3AEA-B323-4466-BBC2-002751D06B0DQ37145264-96813ECA-C9CA-465C-B8FF-0367B7ABFE31Q37147818-5227848F-E557-4453-931F-BEE59AC7DE52Q37207010-82C051A3-19FA-4F24-93DC-950574B5850AQ37207085-3FBA937C-66E0-44E3-BA3F-28FB63CF8958Q37254250-556FBFE5-2380-4E7C-BE0C-7E344DD2C11AQ37345837-805ACC79-63D1-47B9-9050-20C4AF65940DQ37358124-22C0FBE5-F847-4ADD-97A2-F3974FE22D91Q37449635-E542A251-9206-45BB-BA55-81369EF9AD7CQ37456872-1F41249C-E6DF-4BB0-BF03-2521529F91BFQ37593506-CCDDFA56-E37A-4F18-A7C8-77426E1A2D24Q38476881-6E0A20A9-6F55-460A-946D-4535C789B5C6Q38649371-A10F57DC-9B44-4FA9-9518-C34E1AF9AE93Q38957946-C2ABA6E4-43D5-4A40-B140-A364619192A7Q40235244-3D2D92D5-DF1A-4BC2-B296-633E8245AF9EQ42537908-9B827E93-7BFD-433B-8713-22227284C7ADQ52382794-71B8D3A4-27DD-43B6-929A-19601D7AB09BQ54956831-34FE8D16-6A2A-4F84-91B4-5B01D0BE95F0Q55449629-2B1C0F57-352F-44AE-8EDE-61788F22CC4DQ56966479-EC6527C6-FA63-401F-A58D-76C390C1CB76Q58708624-098C9A6A-8BB7-4512-9AA6-3A916160BFCC
P2860
Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis.
@ast
Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis.
@en
type
label
Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis.
@ast
Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis.
@en
prefLabel
Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis.
@ast
Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis.
@en
P2093
P1476
Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis
@en
P2093
P304
P433
5 Suppl 31
P577
2003-09-01T00:00:00Z